Cover Image
市場調查報告書

鮑氏不動桿菌感染疾病:開發中產品分析

Acinetobacter Infections - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 255983
出版日期 內容資訊 英文 119 Pages
訂單完成後即時交付
價格
Back to Top
鮑氏不動桿菌感染疾病:開發中產品分析 Acinetobacter Infections - Pipeline Review, H1 2017
出版日期: 2017年05月16日 內容資訊: 英文 119 Pages
簡介

鮑氏不動桿菌是革蘭氏陰性桿菌。鮑氏不動桿菌感染疾病雖然是不太常見的疾病,但一發病一般則會影響液體內容物(呼吸道和腦脊髓液、腹水、尿道等)多的內臟器官。症狀有發燒(高體溫)、紅腫、發熱或皮膚疼痛、創傷等。原因有免疫系衰弱,衛生狀態不佳,可能會無法接受最新的手術和治療。

本報告提供全球鮑氏不動桿菌感染疾病治療藥的開發趨勢調查,提供您開發中產品的各開發階段比較分析,藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,這個部門的最新趨勢,主要企業的檢討等資訊。

簡介

  • 調查範圍

鮑氏不動桿菌感染疾病概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發中產品
  • 各大學/研究機關的開發中產品
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

鮑氏不動桿菌感染疾病:治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

鮑氏不動桿菌感染疾病的治療藥開發企業

  • Achaogen Inc
  • Adenium Biotech ApS
  • Aridis Pharmaceuticals LLC
  • Atterx Biotherapeutics Inc
  • AvidBiotics Corp
  • Emergent BioSolutions Inc
  • Entasis Therapeutics Inc
  • Evaxion Biotech ApS
  • F. Hoffmann-La Roche Ltd
  • FOB Synthesis Inc
  • Hsiri Therapeutics LLC
  • LegoChem Biosciences Inc
  • Melinta Therapeutics Inc
  • Nosopharm SAS
  • Novabiotics Ltd
  • Omnia Molecular Ltd
  • Peptilogics Inc
  • Pfizer Inc
  • Redx Pharma Plc
  • Sarepta Therapeutics Inc
  • Sealife PHARMA GMBH
  • 鹽野義製藥
  • Techulon Inc
  • Tetraphase Pharmaceuticals Inc
  • Vaxdyn SL
  • Xellia Pharmaceuticals ApS

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9248IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections - Pipeline Review, H1 2017, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape.

Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene and recent surgery or procedure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acinetobacter Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acinetobacter Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acinetobacter Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 3, 28 and 16 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 8 molecules, respectively.

Acinetobacter Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acinetobacter Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Acinetobacter Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acinetobacter Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acinetobacter Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acinetobacter Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acinetobacter Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acinetobacter Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acinetobacter Infections - Overview
    • Acinetobacter Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Acinetobacter Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Acinetobacter Infections - Companies Involved in Therapeutics Development
    • Achaogen Inc
    • Adenium Biotech ApS
    • Aridis Pharmaceuticals LLC
    • Atterx Biotherapeutics Inc
    • AvidBiotics Corp
    • Emergent BioSolutions Inc
    • Entasis Therapeutics Inc
    • Evaxion Biotech ApS
    • F. Hoffmann-La Roche Ltd
    • FOB Synthesis Inc
    • Hsiri Therapeutics LLC
    • LegoChem Biosciences Inc
    • Melinta Therapeutics Inc
    • Nosopharm SAS
    • Novabiotics Ltd
    • Omnia Molecular Ltd
    • Peptilogics Inc
    • Pfizer Inc
    • Redx Pharma Plc
    • Sarepta Therapeutics Inc
    • Sealife PHARMA GMBH
    • Shionogi & Co Ltd
    • Techulon Inc
    • Tetraphase Pharmaceuticals Inc
    • Vaxdyn SL
    • Xellia Pharmaceuticals ApS
  • Acinetobacter Infections - Drug Profiles
    • A-3APO - Drug Profile
    • AA-139 - Drug Profile
    • AB-877 - Drug Profile
    • Acinetobacter vaccine - Drug Profile
    • Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile
    • Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile
    • AR-401 - Drug Profile
    • AvR2-V10 - Drug Profile
    • CA-824 - Drug Profile
    • cefiderocol - Drug Profile
    • CSA-13 - Drug Profile
    • EBX-004 - Drug Profile
    • ETX-2514 + sulbactam sodium - Drug Profile
    • EV-035 - Drug Profile
    • FAB-001 - Drug Profile
    • FSI-1671 - Drug Profile
    • FSI-1686 - Drug Profile
    • G-3KL - Drug Profile
    • GN-4474 - Drug Profile
    • HT-06 - Drug Profile
    • HT-07 - Drug Profile
    • HT-10 - Drug Profile
    • JSM-11 - Drug Profile
    • LCB-100200 - Drug Profile
    • MDN-0057 - Drug Profile
    • Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile
    • NOSO-95179 - Drug Profile
    • NP-432 - Drug Profile
    • Peptides for Infectious Diseases - Drug Profile
    • pneumonia vaccine - Drug Profile
    • RX-05 - Drug Profile
    • RXP-873 - Drug Profile
    • SLP-0901 - Drug Profile
    • SLP-0905 - Drug Profile
    • Small Molecule for Acinetobacter baumannii Infections - Drug Profile
    • Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile
    • Small Molecule to Target Bacterial Cell Membrane for Acinetobacter Infections - Drug Profile
    • Small Molecules for Acinetobacter baumannii Infection - Drug Profile
    • Small Molecules for Bacterial and Fungal Infections - Drug Profile
    • Small Molecules for Bacterial Infections - Drug Profile
    • Small Molecules for Bacterial Infections - Drug Profile
    • Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile
    • Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections - Drug Profile
    • Small Molecules to Inhibit DNA Gyrase Subunit A and Topoisomerase IV for Gram-Negative Bacterial Infections - Drug Profile
    • Small Molecules to Inhibit LpxC for Gram Negative Bacterial Infections - Drug Profile
    • Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections and Respiratory Diseases - Drug Profile
    • Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections - Drug Profile
    • SPR-741 - Drug Profile
    • Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections - Drug Profile
    • Synthetic Peptides for Infectious Disease - Drug Profile
    • TN-5 - Drug Profile
    • TP-6076 - Drug Profile
    • VNRX-5113 - Drug Profile
    • VXD-001 - Drug Profile
    • VXD-003 - Drug Profile
    • XEL-1001 - Drug Profile
    • XEL-1002 - Drug Profile
    • XEL-1003 - Drug Profile
    • XEL-1007 - Drug Profile
  • Acinetobacter Infections - Dormant Projects
  • Acinetobacter Infections - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Acinetobacter Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Acinetobacter Infections - Pipeline by Achaogen Inc, H1 2017
  • Acinetobacter Infections - Pipeline by Adenium Biotech ApS, H1 2017
  • Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
  • Acinetobacter Infections - Pipeline by Atterx Biotherapeutics Inc, H1 2017
  • Acinetobacter Infections - Pipeline by AvidBiotics Corp, H1 2017
  • Acinetobacter Infections - Pipeline by Emergent BioSolutions Inc, H1 2017
  • Acinetobacter Infections - Pipeline by Entasis Therapeutics Inc, H1 2017
  • Acinetobacter Infections - Pipeline by Evaxion Biotech ApS, H1 2017
  • Acinetobacter Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Acinetobacter Infections - Pipeline by FOB Synthesis Inc, H1 2017
  • Acinetobacter Infections - Pipeline by Hsiri Therapeutics LLC, H1 2017
  • Acinetobacter Infections - Pipeline by LegoChem Biosciences Inc, H1 2017
  • Acinetobacter Infections - Pipeline by Melinta Therapeutics Inc, H1 2017
  • Acinetobacter Infections - Pipeline by Nosopharm SAS, H1 2017
  • Acinetobacter Infections - Pipeline by Novabiotics Ltd, H1 2017
  • Acinetobacter Infections - Pipeline by Omnia Molecular Ltd, H1 2017
  • Acinetobacter Infections - Pipeline by Peptilogics Inc, H1 2017
  • Acinetobacter Infections - Pipeline by Pfizer Inc, H1 2017
  • Acinetobacter Infections - Pipeline by Redx Pharma Plc, H1 2017
  • Acinetobacter Infections - Pipeline by Sarepta Therapeutics Inc, H1 2017
  • Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H1 2017
  • Acinetobacter Infections - Pipeline by Shionogi & Co Ltd, H1 2017
  • Acinetobacter Infections - Pipeline by Techulon Inc, H1 2017
  • Acinetobacter Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
  • Acinetobacter Infections - Pipeline by Vaxdyn SL, H1 2017
  • Acinetobacter Infections - Pipeline by Xellia Pharmaceuticals ApS, H1 2017
  • Acinetobacter Infections - Dormant Projects, H1 2017
  • Acinetobacter Infections - Dormant Projects, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Acinetobacter Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top